‹

Fexolinetant

›

‹

›


Product name: Fexolinetant,Birinapant

CAS No.:  1629229-37-3

MF: C16H15FN6OS

M.W.: 358.39

Capacity:  10KG/M 

Usage:  R&D&Pipeline

INQUIRY NOW

■ Description

Description:Fezolinetant is an oral small molecule neurokinin-3 receptor (NK3R) antagonist developed by Astellas Pharma Inc. for the treatment of moderate to severe vasoconstrictive symptoms (VMS) or menopausal hot flashes. Fezolinetant is a non hormonal strategy that regulates neuronal activity related to temperature regulation by inhibiting NK3R mediated signaling in the central nervous system, thereby reducing the frequency and severity of VMS.

Origin:Fezolinetant was first approved in the United States in May 2023 for the treatment of moderate to severe vasoconstrictive symptoms (VMS) caused by menopause.

■ Message

SUBMIT